Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
18.45
-0.26 (-1.39%)
Sep 4, 2026, 4:00 PM EDT - Market closed
Takeda Pharmaceutical Company Employees
Takeda Pharmaceutical Company had 47,029 employees as of March 31, 2026. The number of employees decreased by 426 or -0.90% compared to the previous year.
Employees
47,029
Change (1Y)
-426
Growth (1Y)
-0.90%
Revenue / Employee
$604,230
Profits / Employee
-$21,380
Market Cap
58.86B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 47,029 | -426 | -0.90% |
| Mar 31, 2025 | 47,455 | -1,826 | -3.71% |
| Mar 31, 2024 | 49,281 | 186 | 0.38% |
| Mar 31, 2023 | 49,095 | 1,748 | 3.69% |
| Mar 31, 2022 | 47,347 | 248 | 0.53% |
| Mar 31, 2021 | 47,099 | -396 | -0.83% |
| Mar 31, 2020 | 47,495 | -2,083 | -4.20% |
| Mar 31, 2019 | 49,578 | 22,348 | 82.07% |
| Mar 31, 2018 | 27,230 | -2,670 | -8.93% |
| Mar 31, 2017 | 29,900 | -1,268 | -4.07% |
| Mar 31, 2016 | 31,168 | -160 | -0.51% |
| Mar 31, 2015 | 31,328 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Teva Pharmaceutical Industries | 33,950 |
| Viatris | 30,000 |
| Dr. Reddy's Laboratories | 27,527 |
| Haleon | 24,535 |
| Zoetis | 14,500 |
| Elanco Animal Health | 9,900 |
| Hims & Hers Health | 2,442 |
| Alkermes | 2,050 |
TAK News
- 2 days ago - Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? - Nasdaq
- 3 days ago - Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities - Business Wire
- 4 days ago - Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers - CNBC
- 4 days ago - Trump administration to announce drug pricing deals - Reuters
- 5 days ago - Protagonist announces Takeda received U.S. FDA approval for MIMRYLO - TheFly
- 7 days ago - FDA Approves Takeda's Mimrylo For Rare Blood Disorder Polycythemia Vera - Nasdaq
- 7 days ago - Takeda receives FDA approval of NDA for Mimrylo - TheFly
- 7 days ago - Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera - Business Wire